MatriTek Launches Commercial Operations

matritek-logoNEW YORK — MatriTek, Inc., a biotechnology company specializing in tissue-specific cell culture biomaterials, announced the launch of commercial production of novel extracellular matrix (ECM) biomaterials for biomedical research at the Alexandria Center for Life Sciences on East 29th Street.

MatriTek’s proprietary TissueSpec platform technology enables scientists to culture cells in a physiologically relevant extracellular microenvironment and is coupled with the company’s core expertise in cell and tissue culture biomaterials and in-vitro models for biomedical research. MatriTek’s novel ECM biomaterials are fully customized to address research needs in cell biology, stem cell and cancer research, and regenerative medicine.

MatriTek, Inc. is headquartered in New York City with production and R&D facilities at the Alexandria Center for Life Science.

MatriTek’s cutting-edge technology was developed by a team led by Dr. Gordana Vunjak Novakovic, Mikati Foundation Professor of Biomedical Engineering and Professor of Medical Sciences at Columbia University, demonstrating the potential for a broad range of applications in stem cell research and regenerative medicine. Dr. Vunjak Novakovic is a renowned expert in tissue engineering and a member of the American Institute for Medical and Biological Engineering, Academia Europaea, National Academy of Engineering, National Academy of Medicine, and National Academy of Inventors.

“I am really excited about launching MatriTek’s line of tissue-specific cell culture products, as they fulfill the long-standing need for culturing cells in a native-like environment,” said Dr. Gordana Vunjak Novakovic. “These extracellular matrix biomaterials could have a major impact on studies of cells and tissues in the context of development, regeneration, and the modeling of disease.”

“It’s the simple idea of mimicking nature. MatriTek was created to address the needs of life science researchers for natural, physiological microenvironments in which to grow and study cells and tissues,” said John O’Neill, MatriTek co-founder and lead inventor. “Extracellular matrix, a major component of tissues, supports and regulates cell growth and tissue function.  Our team has isolated and validated a number of widely used tissue-specific matrices that provide native physiological conditions as well as signaling and regulatory functions highly specific to each tissue.”

“We are so pleased that MatriTek is bringing this technology platform to market,” said Beth Kauderer from Columbia Technology Ventures, the technology transfer office at Columbia University, “as we believe the platform will have important applications in oncology, neuroscience, pharmacology, toxicology, regenerative medicine, and other fields.

 

“MatriTek continues to evolve and advance its TissueSpecTM platform with a focus on research needs in the life sciences,” saidLjiljana Kundakovic, Chief Executive Officer of MatriTek. “We are taking critical steps to ensure that MatriTek’s technology and development capabilities are made available to scientists worldwide.”